You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

Select Your Country or Region


Reporting period January – March

PRESS RELEASE  2013-04-17                                                                                                                                                                                                                                                                             

Reporting period January – March

  • Order intake rose by 3.0% to SEK 5,968 M (5,795), and grew organically by 1.8%
  • Net sales increased by 8.0% to SEK 5,664 M (5,246), and grew organically by 6.6%
  • Profit before tax declined by 55.8% to SEK 252 M (570). Profit was charged with SEK 240 M (0) in restructuring costs.
  • Earnings per share decreased by 56.8% to SEK 0.76 (1.76)
  • EBITA before restructuring declined by 7.3% to SEK 792 M (854). Adjusted for currency effects and the Medical Device Tax introduced in the US, EBITA rose by 8%

First quarter 2013

While demand for the Group’s medical-technical capital goods continues to experience a challenge in the Western European market, which has yet to hit bottom, volume expectations in the markets outside Western Europe improved during the quarter. Work on strengthening the Group’s competitiveness and profitability continue, and a number of efficiency enhancement projects were initiated during the quarter.

Orders received

The Group’s order intake increased organically by 1.8% during the quarter. For the Group’s largest business area, Medical Systems, order intake grew organically by a highly favourable 7.5%, with strong growth in the Cardiovascular and Critical Care division. For Extended Care, which has considerable exposure to the elderly care sector and the more mature Western European and North American markets, order intake declined organically by 4.2%. In Infection Control, order intake declined organically by 4.6%. While a weaker Life Science market resulted in a volume decline for Infection Control, demand from hospital customers experienced a strong trend.

Demand in the Western European markets remains challenging and difficult to assess, particularly in terms of the southern European markets. The North American market has stabilized and all business areas reported a positive volume trend in the US during the quarter. The demand scenario remains robust in the markets outside Western Europe and North America.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander
17 April 2013 at 3:00 p.m. Swedish time

Swedish dial in number: +46 8 5853 6965
UK dial in number: +44 20 3478 5300
US dial in number: +1 212 444 0412

Participant passcode: 224195

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.